Read the Canadian Cancer Trials Group story on results from a pre-planned secondary analysis of the PR21 PLUDO trial. Presented during the Genitourinary Cancer Session at the American Society of Clinical Oncology Annual Meeting 2026, the study focuses on treatment sequencing in patients with metastatic castration-resistant prostate cancer (mCRPC). These findings were presented by Dr. Kim Chi, medical oncologist at BC Cancer – Vancouver.